Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilpivirine long-acting
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Rilpivirine long-acting (LA) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) formulated as an extended-release injectable suspension for the treatment of HIV-1 infection. It is administered as an intramuscular injection in the buttocks, typically alongside cabotegravir long-acting (CAB LA). This combination forms a complete long-acting regimen for maintenance therapy in virologically suppressed HIV patients. The long-acting formulation allows for dosing every 1-2 months, providing an alternative to daily oral medication.
- Brand names
- Rekambys
- Other names
- rilpivirine LA
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on rilpivirine long-acting.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilpivirine long-acting.